Psoriatic Arthritis

The presence of cardiac troponin I may indicate a risk for atherosclerosis in patients with psoriatic disease independently from traditional cardiovascular risk factors, according to data published in Arthritis and Rheumatology.

While biologic therapy persistence rates were generally low at 3 years, interleukin-17 inhibitors were generally more persistent than tumor necrosis factor inhibitors in both psoriasis and psoriatic arthritis, according to a study.

Patients with psoriatic arthritis or ankylosing spondylitis who received once daily upadacitinib 15 mg experienced improvements in pain measures through 1 year, according to data published in RMD Open.

Deucravacitinib, a TYK2 inhibitor, was well-tolerated and superior to placebo in improving ACR20 response among patients with psoriatic arthritis, according to data published in the Annals of the Rheumatic Diseases.

Patients with rheumatic and musculoskeletal diseases should engage in both aerobic and strengthening exercises, aiming for at least moderate intensity, according to new EULAR recommendations.

Development of rheumatoid arthritis, or another such inflammatory disease, often brings with it a mental toll.

Tofacitinib for psoriatic arthritis is efficacious in most patient-reported and clinical endpoints over time, and shows shorter initial and meaningful response times versus switching from placebo to the drug at month 3, noted researchers.

The use of analgesics is more common in those with psoriasis, specifically those with concomitant psoriatic arthritis, than in the general population, according to a study.

Secukinumab provides early, clinically meaningful, statistically significant and sustained improvements in patient-reported outcomes across all doses, compared with placebo, in active psoriatic arthritis, according to data.

WAILEA, Hawaii — Guselkumab showed better efficacy in psoriasis skin clearance than most psoriatic arthritis treatments, according to a meta-analysis presented at Maui Derm for Dermatologists.